Antiangiogenic isoforms of vascular endothelial growth factor predominate in subretinal fluid of patients with rhegmatogenous retinal detachment and proliferative vitreoretinopathy

Retina

Volumn 32, Issue 1, 2012, Pages 54-59

  Ricker, Lukas J A G ^a,b   Dieudonné, Suzanne C ^a   Kessels, Alfons G H ^a   Rennel, Emma S ^c   Berendschot, Tos T J M ^a   Hendrikse, Fred ^a   Kijlstra, Aize ^a   La Heij, Ellen C ^a  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^b European Graduate School For Neuroscience   (Netherlands)

^c UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

proliferative vitreoretinopathy; rhegmatogenous retinal detachment; subretinal fluid; vascular endothelial growth factor; VEGF isoforms

Indexed keywords

ANGIOGENIC FACTOR; ANGIOGENIC VASCULAR ENDOTHELIAL GROWTH FACTOR ISOFORM; ANTIANGIOGENIC VASCULAR ENDOTHELIAL GROWTH FACTOR ISOFORM; UNCLASSIFIED DRUG; VASCULOTROPIN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN TISSUE; MALE; PROTEIN EXPRESSION; PROTEIN STRUCTURE, FUNCTION AND VARIABILITY; RETINA DETACHMENT; RETINA DISEASE; SUBRETINAL FLUID; UNCOMPLICATED RHEGMATOGENOUS RETINA DETACHMENT; VISUAL ACUITY; VITREORETINOPATHY;

ADULT; AGED; AGED, 80 AND OVER; ANGIOGENESIS INDUCING AGENTS; ANGIOGENESIS INHIBITORS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MALE; MIDDLE AGED; PROTEIN ISOFORMS; RETINAL DETACHMENT; SUBRETINAL FLUID; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VITREORETINOPATHY, PROLIFERATIVE; YOUNG ADULT;

EID: 84855203266     PISSN: 0275004X     EISSN: 15392864     Source Type: Journal    
DOI: 10.1097/IAE.0b013e31821800b9     Document Type: Article

References (27)

1. Witmer AN, Vrensen GF, Van Noorden CJ, Schlingemann RO. Vascular endothelial growth factors and angiogenesis in eye disease. Prog Retin Eye Res 2003;22:1-29. (Pubitemid 36207453)
2. Su CY, Chen MT, Wu WS, Wu WC. Concentration of vascular endothelial growth factor in the subretinal fluid of retinal detachment. J Ocul Pharmacol Ther 2000;16:463-469.
3. Ogata N, Nishikawa M, Nishimura T, et al. Inverse levels of pigment epithelium-derived factor and vascular endothelial growth factor in the vitreous of eyes with rhegmatogenous retinal detachment and proliferative vitreoretinopathy. Am J Ophthalmol 2002;133:851-852. (Pubitemid 34580647)
4. Moromizato Y, Hayashi H, Kato H, et al. Concentration of vascular endothelial growth factor within the subretinal space and vitreous fluid in rhegmatogenous retinal detachment. J Jpn Ophthalmol Soc 1997;101:498-502. (Pubitemid 27265384)
5. Aiello LP, Avery RL, Arrigg PG, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 1994; 331:1480-1487. (Pubitemid 24356306)
6. Vinores SA, Campochiaro PA, Conway BP. Ultrastructural and electron-immunocytochemical characterization of cells in epiretinal membranes. Invest Ophthalmol Vis Sci 1990;31: 14-28. (Pubitemid 20042460)
7. Adamis AP, Shima DT, Yeo KT, et al. Synthesis and secretion of vascular permeability factor/vascular endothelial growth factor by human retinal pigment epithelial cells. Biochem Biophys Res Commun 1993;193:631-638. (Pubitemid 23214274)
8. Hata Y, Nakagawa K, Ishibashi T, et al. Hypoxia-induced expression of vascular endothelial growth factor by retinal glial cells promotes in vitro angiogenesis. Virchows Arch 1995;426: 479-486.
9. Ladomery MR, Harper SJ, Bates DO. Alternative splicing in angiogenesis: the vascular endothelial growth factor paradigm. Cancer Lett 2007;249:133-142. (Pubitemid 46452926)
10. Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev 2004;25:581-611. (Pubitemid 39099316)
11. Bates DO, Cui TG, Doughty JM, et al. VEGF165b, an inhibitory splice variant of vascular endothelial growth factor, is down-regulated in renal cell carcinoma. Cancer Res 2002;62:4123-4131. (Pubitemid 34791084)
12. WoolardJ, Wang WY, Bevan HS, etal. VEGF165b, an inhibitory vascular endothelial growth factor splice variant: mechanism of action, in vivo effect on angiogenesis and endogenous protein expression. Cancer Res 2004;64:7822-7835. (Pubitemid 39446915)
13. Ricker LJAG, Kijlstra A, de Jager W, et al. Chemokine levels in subretinal fluid obtained during scleral buckling surgery after rhegmatogenous retinal detachment. Invest Ophthalmol Vis Sci 2010;51:4143-4150.
14. Machemer R, Aaberg TM, Freeman HM, et al. An updated classification of retinal detachment with proliferative vitreor-etinopathy. Am J Ophthalmol 1991;112:159-165.
15. Varey AH, Rennel ES, Qiu Y, et al. VEGF 165 b, an antiangiogenic VEGF-A isoform, binds and inhibits bevaci-zumab treatment in experimental colorectal carcinoma: balance of pro-and antiangiogenic VEGF-A isoforms has implications for therapy. Br J Cancer 2008;98:1366-1379. (Pubitemid 351543576)
16. Chen YS, Hackett SF, Schoenfeld CL, et al. Localisation of vascular endothelial growth factor and its receptors to cells of vascular and avascular epiretinal membranes. Br J Ophthalmol 1997;81:919-926. (Pubitemid 27469979)
17. Rennel E, Waine E, Guan H, et al. The endogenous anti-angiogenic VEGF isoform, VEGF165b inhibits human tumour growth in mice. Br J Cancer 2008;98:1250-1257. (Pubitemid 351481687)
18. Perrin RM, Konopatskaya O, Qiu Y, et al. Diabetic retinopathy is associated with a switch in splicing from anti-to pro-angiogenic isoforms of vascular endothelial growth factor. Diabetologia 2005;48:2422-2427. (Pubitemid 41618935)
19. Tsanou E, Ioachim E, Stefaniotou M, et al. Immunohisto-chemical study of angiogenesis and proliferative activity in epiretinal membranes. Int J Clin Pract 2005;59:1157-1161. (Pubitemid 43904521)
20. Dawczynski J, Janz S, Kasper M, et al. Histologische und immunhistologische Untersuchungen humaner epiretinaler Membranen. Klin Monatsbl Augenheilkd 2006;223: 687-690. (Pubitemid 44681090)
21. Asiyo-Vogel MN, El-Hifnawi ES, Bopp S, Laqua H. The vascular component of proliferative vitreoretinopathy membranes: an immunohistochemical and ultrastructural study. Retina 1998;18:56-61. (Pubitemid 28128406)
22. Armstrong D, Augustin AJ, Spengler R, et al. Detection of vascular endothelial growth factor and tumor necrosis factor alpha in epiretinal membranes of proliferative diabetic retinopathy, proliferative vitreoretinopathy and macular pucker. Ophthalmologica 1998;212:410-414. (Pubitemid 28446600)
23. Ogata N, Nishikawa M, Nishimura T, et al. Unbalanced vitreous levels of pigment epithelium-derived factor and vascular endothelial growth factor in diabetic retinopathy. Am J Ophthalmol 2002;134:348-353.
24. Dieudonne SC, La Heij EC, Diederen RM, et al. Balance of vascular endothelial growth factor and pigment epithelial growth factor prior to development of proliferative vitreor-etinopathy. Ophthalmic Res 2007;39:148-154. (Pubitemid 46975980)
25. Saint-Geniez M, Maharaj AS, Walshe TE, et al. Endogenous VEGF is required for visual function: evidence for a survival role on Müller cells and photoreceptors. PLoS ONE 2008;3: e3554.
26. Clauss M, Gerlach M, Gerlach H, et al. Vascular permeability factor: a tumor-derived polypeptide that induces endothelial cell and monocyte procoagulant activity, and promotes monocyte migration. J Exp Med 1990;172:1535-1545.
27. Martin F, Pastor JC, De La Rua ER, et al. Proliferative vitreoretinopathy: cytologic findings in vitreous samples. Ophthalmic Res 2003;35:232-238. (Pubitemid 36736952)